ADReCS

Pharmaceutical Information

Drug Name	Hydroxyurea
Drug ID	BADD_D01110
Description	An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage	For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status	approved
ATC Code	L01XX05
DrugBank ID	DB01005
KEGG ID	D00341
MeSH ID	D006918
PubChem ID	3657
TTD Drug ID	D07CWD
NDC Product Code	0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII	X6Q56QN5QC
Synonyms	Hydroxyurea \| Hydroxycarbamid \| Oncocarbide \| Hydrea

Chemical Information

Molecular Formula	CH4N2O2
CAS Registry Number	127-07-1
SMILES	C(=O)(N)NO
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hernia	08.01.04.001	0.000280%		-
Hyperglycaemia	05.06.02.002; 14.06.02.002	0.000168%
Hyperkalaemia	14.05.03.001	0.000448%
Hyperkeratosis	23.01.01.001	0.000112%
Hypersensitivity	10.01.03.003	-	-
Hypersensitivity vasculitis	01.01.04.008; 10.02.02.017; 23.06.02.005; 24.12.04.013	0.000168%		-
Hypersplenism	01.09.02.002	0.000168%		-
Hyperuricaemia	14.09.01.003	0.000224%
Hypocalcaemia	14.04.01.004	0.000112%
Hypoglycaemia	05.06.03.001; 14.06.03.001	0.000358%
Hypomagnesaemia	14.04.02.001	-	-
Hyponatraemia	14.05.04.002	0.000280%
Hypoxia	22.02.02.003	0.000168%
Ileal ulcer	07.04.06.008	0.000112%
Ileus	07.13.01.001	0.000112%
Impaired healing	08.03.02.001	0.000358%		-
Increased tendency to bruise	01.01.03.005; 23.06.01.009; 24.07.06.012	0.000112%		-
Infection	11.01.08.002	-	-	-
Inguinal hernia	07.16.02.001	0.000168%		-
Interstitial lung disease	10.02.01.033; 22.01.02.003	0.001959%		-
Intestinal obstruction	07.13.01.002	0.000112%		-
Iron deficiency anaemia	01.03.01.002; 14.13.02.001	0.000112%		-
Jaundice	01.06.04.004; 09.01.01.004; 23.03.03.030	-	-	-
Large intestinal ulcer	07.04.06.004	0.000112%
Laryngeal cancer	16.19.03.001; 22.08.02.001	0.000112%		-
Leukaemia	01.10.03.001; 16.01.03.001	0.000336%
Leukocytosis	01.02.01.002	0.000783%
Leukopenia	01.02.02.001	0.000224%		-
Liver disorder	09.01.08.001	0.000504%		-
Lung disorder	22.02.07.001	0.000168%		-

The 5th Page First Pre 5 6 7 8 9 Next Last Total 13 Pages